- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07805135
A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
3. September 2026 aktualisiert von: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
A Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer
This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.
Studienübersicht
Status
Noch keine Rekrutierung
Bedingungen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Geschätzt)
430
Phase
- Phase 3
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Clinical Trials Information Group Officer
- Telefonnummer: 86-0311-69085587
- E-Mail: ctr-contact@cspc.cn
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- 1. Age: 18-75 years (Whichever is on the day of signing the informed consent form).
2. Subjects have histologically or cytologically confirmed breast cancer at unresectable,recurrent/metastatic stage, with the requirements below based on the most recent pathological report:
- HER2-negative confirmed by histological or cytological testing;
- Pathological report is available to confirm HR status.
- 3. Assessed by the Investigator as suitable for single-agent docetaxel therapy.
- 4. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
- 5. Has adequate organ and system functions within 7 days prior to the first dose.
- 6. Eastern Cooperative Oncology Group performance status of 0 or 1.
- 7. Expected survival ≥ 3 months.
Exclusion Criteria:
- 1. Has received prior taxane-containing single-agent or combination regimens, and have disease progression during salvage therapy for unresectable locally advanced or metastatic breast cancer (has received at least 2 cycles), or developed recurrent-metastatic disease within 12 months following adjuvant therapy.
- 2. History of severe allergy or hypersensitivity reactions (Grade ≥3 per NCI-CTCAE Version 6.0) to human serum albumin or docetaxel and/or contraindications thereto, or history of severe allergy and/or contraindications to glucocorticoids.
- 3. Untreated active brain metastases (including brain or leptomeningeal metastases). Subjects with treated brain metastases may be enrolled if lesions are stable without evidence of new or enlarging pre-existing brain metastases.
- 4. With a history of other primary malignant tumors within 5 years before administration.
- 5. Presence of serous cavity effusion requiring drainage or diuretic therapy within 2 weeks prior to the first dose.
- 6. Severe neurological diseases (e.g., epilepsy, dementia, etc.) and Grade ≥2 peripheral neuropathy.
- 7. Receipt of systemic glucocorticoid therapy within 14 days prior to the first dose.
- 8. Current clinically significant abnormal interstitial lung disease.
- 9. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to the first dose.
- 10. Has arterial or venous thromboembolism (e.g., lower-extremity deep vein thrombosis, lower-extremity arterial embolism, pulmonary embolism, etc.) within 6 months prior to the first dose. Stable thrombus is permitted for enrollment if the Investigator assesses no associated cardiovascular risk.
- 11. Severe chronic or active infection requiring intravenous antibacterial, antifungal, or antiviral therapy within 2 weeks prior to the first dose.
- 12. Has undergone major visceral organ surgery (excluding puncture biopsy or infusion device implantation) within 4 weeks prior to the first dose, or who require major visceral organ surgery during the study period.
- 13. Receipt of chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or other investigational study drug within 4 weeks or 5 half-lives prior to the first dose (whichever is shorter, with a minimum of 2 weeks); receipt of radiotherapy within 2 weeks prior to the first dose; receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose.
- 14. Toxicities from all prior anti-tumor therapies have not recovered to Grade 1 or less prior to the first dose.
- 15. Has received powerful CYP3A4 inhibitor or inducer within 2 weeks before the first dose.
- 16. Has active hepatitis B infection, hepatitis C infection, positive HIV antibody, or active syphilis.
- 17. Concurrent participation in another interventional clinical study.
- 18. Any other conditions that, in the Investigator's opinion, render the participant unsuitable for participation in this clinical trial.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: HB1801
|
HB1801, 100 mg/m² in Cycle 1, 75 mg/m² starting from Cycle 2, once every 3 weeks (Q3W), intravenous infusion over 60 minutes.
|
|
Experimental: Docetaxel (Taxotere®)
|
Docetaxel (Taxotere®), 75 mg/m², Q3W, intravenous infusion over 60 minutes.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free Survival (PFS)
Zeitfenster: up to approximately 2 years after the first enrollment
|
PFS was defined as the time from the date of randomization to the date of progressive disease (as per RECIST v1.1) or death due to any cause.
|
up to approximately 2 years after the first enrollment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Objective Response Rate (ORR) assessed per RECIST v1.1
Zeitfenster: up to approximately 2 years after the first enrollment
|
ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with complete response (CR) or partial response (PR).
|
up to approximately 2 years after the first enrollment
|
|
Duration of Response (DOR)
Zeitfenster: up to approximately 2 years after the first enrollment
|
DOR by investigator assessment according to RECIST 1.1 in participants with CR or PR, defined as the time from the first documented CR/PR to PD or death.
|
up to approximately 2 years after the first enrollment
|
|
Disease Control Rate (DCR)
Zeitfenster: up to approximately 2 years after the first enrollment
|
DCR by investigator assessment according to RECIST 1.1, defined as the percentage of participants with CR, PR, or stable disease (SD) lasting at least 6 weeks.
|
up to approximately 2 years after the first enrollment
|
|
Overall Survival (OS)
Zeitfenster: up to approximately 2 years after the first enrollment
|
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from study therapy or received another subsequent anticancer therapy.
|
up to approximately 2 years after the first enrollment
|
|
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Zeitfenster: up to approximately 2 years after the first enrollment
|
up to approximately 2 years after the first enrollment
|
|
|
Plasma concentration of docetaxel (free and total)
Zeitfenster: After completion of infusion administration on Day 1 of Cycle 1
|
After completion of infusion administration on Day 1 of Cycle 1
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
31. August 2026
Primärer Abschluss (Geschätzt)
1. Juni 2028
Studienabschluss (Geschätzt)
1. Juni 2029
Studienanmeldedaten
Zuerst eingereicht
28. August 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
3. September 2026
Zuerst gepostet (Tatsächlich)
4. September 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
4. September 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
3. September 2026
Zuletzt verifiziert
1. September 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HB1801-017
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .